Student or educator? Sign up with your school email and get 6 months of Pro free.
CoChat

The DOI matches its Crossref record; 33 of the 33 references it cites were found in a registry or an index.

Anti-fibrotic therapy and lung transplant outcomes in patients with idiopathic pulmonary fibrosis

Open access

Abstract

Background: It is unclear whether continuing anti-fibrotic therapy until the time of lung transplant increases the risk of complications in patients with idiopathic pulmonary fibrosis. Objectives: To investigate whether the time between discontinuation of anti-fibrotic therapy and lung transplant in patients with idiopathic pulmonary fibrosis affects the risk of complications. Methods: We assessed intra-operative and post-transplant complications among patients with idiopathic pulmonary fibrosis who underwent lung transplant and had been treated with nintedanib or pirfenidone continuously for ⩾ 90 days at listing. Patients were grouped according to whether they had a shorter (⩽ 5 medication half-lives) or longer (> 5 medication half-lives) time between discontinuation of anti-fibrotic medication and transplant. Five half-lives corresponded to 2 days for nintedanib and 1 day for pirfenidone. Results: Among patients taking nintedanib ( n = 107) or pirfenidone ( n = 190), 211 (71.0%) had discontinued anti-fibrotic therapy ⩽ 5 medication half-lives before transplant. Anastomotic and sternal dehiscence occurred only in this group (anastomotic: 11 patients [5.2%], p = 0.031 vs patients with longer time between discontinuation of anti-fibrotic medication and transplant; sternal: 12 patients [5.7%], p = 0.024). No differences were observed in surgical wound dehiscence, length of hospital stay, or survival to discharge between groups with a shorter versus longer time between discontinuation of anti-fibrotic therapy and transplant. Conclusion: Anastomotic and sternal dehiscence only occurred in patients with idiopathic pulmonary fibrosis who discontinued anti-fibrotic therapy < 5 medication half-lives before transplant. The frequency of other intra-operative and post-transplant complications did not appear to differ depending on when anti-fibrotic therapy was discontinued. Registration: clinicaltrials.gov NCT04316780: https://clinicaltrials.gov/ct2/show/NCT04316780

Overview

The claims and statistics of this paper haven’t been checked yet.

Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.

A few free checks a day · papers already verified open instantly · results are public

Integrity signals

Registry

Crossref · 10.1177/17534666231165912

Cites

33 of 33 references verified0 citation errors · 0 not checkable

Statistics

Figures

Figure 1. Percentages of patients with anastomotic dehiscence, surgical wound dehiscence and sternal dehiscence by time between discontinuation of anti-fibrotic medication and transplant. Shorter: discontinued anti-fibrotic medication ⩽ 5 medication half-lives before transplant; longer: discontinued anti-fibrotic medication > 5 medication half-lives before transplant.
Figure 1. Percentages of patients with anastomotic dehiscence, surgical wound dehiscence and sternal dehiscence by time between discontinuation of anti-fibrotic medication and transplant. Shorter: discontinued anti-fibrotic medication ⩽ 5 medication half-lives before transplant; longer: discontinued anti-fibrotic medication > 5 medication half-lives before transplant.CC BY-NC · PubMed Central

Verification

Claims the paper makes

The claims and statistics of this paper haven’t been checked yet.

Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.

A few free checks a day · papers already verified open instantly · results are public

Claims other papers make about this one

Each is checked against this paper’s own text: does it say what the citing paper says it does?

Self-check

Percentages, sums and reported differences re-computed from the paper’s own numbers.

The self-check needs the paper’s full text.

Citations

Cites

Show all 33 references

Cited by

See all 11

Metadata

Authors
Astor, T. L., Goldberg, H. J., Snyder, L. D., Courtwright, A., Hachem, R., Pena, T., Zaffiri, L., Criner, G. J., Budev, M. M., Thaniyavarn, T., Leonard, T. B., Bender, S., Barakat, A., Breeze, J. L., & LaCamera, P.
Affiliations
  • Massachusetts General Hospital (US)
  • Brigham and Women's Hospital (US)
  • Duke University (US)
  • University of Pennsylvania (US)
  • Washington University in St. Louis (US)
  • University of Iowa (US)
  • Temple University (US)
  • Cleveland Clinic (US)
  • Boehringer Ingelheim (United States) (US)
  • ILD Collaborative, Boston, MA, USA
  • Tufts University (US)
  • St. Elizabeth's Medical Center (US)
Corresponding author
LaCamera, Peter
Venue
Therapeutic Advances in Respiratory Disease
Published
2023-01
Volume
17
Pages
17534666231165912-17534666231165912
ISSN
  • 1753-4658 (ISSN-L)
  • 1753-4666
OpenAlex
W4366351092
Cited by
8
References
33
Citations by year
2026: 1 · 2025: 3 · 2024: 3 · 2023: 1
FWCI
2.14
Type
journal article
Language
en
Open access
Locations
  • Therapeutic Advances in Respiratory Disease (publishedVersion, cc-by-nc)
  • PubMed Central (publishedVersion, cc-by-nc)
  • PubMed (publishedVersion)
  • Digital Commons@Becker (Washington University School of Medicine) (submittedVersion, cc-by-nc)
  • DOAJ (DOAJ: Directory of Open Access Journals) (submittedVersion, cc-by-sa)
Funders
This study was funded by Boehringer Ingelheim Pharmaceuticals, Inc (BIPI).
Topics
  • Health Sciences › Medicine › Surgery › Transplantation: Methods and Outcomes
  • Health Sciences › Medicine › Pulmonary and Respiratory Medicine › Interstitial Lung Diseases and Idiopathic Pulmonary Fibrosis
  • Health Sciences › Medicine › Pulmonary and Respiratory Medicine › Pulmonary Hypertension Research and Treatments
Keywords
idiopathic pulmonary fibrosis, lung transplantation, antifibrotic therapy, nintedanib, pirfenidone, anastomotic leakage, sternal dehiscence, post-transplant complications, surgical wound complications
MeSH terms
Fibrosis, Humans, Lung Transplantation, Treatment Outcome, Idiopathic Pulmonary Fibrosis

About these checks

Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.

Statistics and arithmetic are recomputed, not judged.

Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.

What counts as a claim ›How we measure confidence ›How we check this ›

Are you an author, or do you see a problem with this page? Request a review

How to cite

Cite CoChat for the checks on this page, and the paper for its own findings.

This page
CoChat. (2026). Citation check: Anti-fibrotic therapy and lung transplant outcomes in patients with idiopathic pulmonary fibrosis. https://app.cochat.ai/papers/10.1177/17534666231165912
The paper
Astor, T. L., Goldberg, H. J., Snyder, L. D., Courtwright, A., Hachem, R., Pena, T., Zaffiri, L., Criner, G. J., Budev, M. M., Thaniyavarn, T., Leonard, T. B., Bender, S., Barakat, A., Breeze, J. L., & LaCamera, P. (2023). Anti-fibrotic therapy and lung transplant outcomes in patients with idiopathic pulmonary fibrosis. Therapeutic Advances in Respiratory Disease. https://doi.org/10.1177/17534666231165912

Data sources

Bibliographic data: Semantic Scholar, OpenAlex, Crossref.

Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).

Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.